Abstract:
Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.
Abstract:
A presente invenção se refere a um processo para a produção de uma linhagem celular contínua de células tronco embrionárias simile, como exemplo, Amblyomma sculptum (Acari: Ixodidae) denominada IBU/ASE-16 (número de acesso no CNCM: I-5000) e seus usos. Mais especificamente, a presente invenção se refere ao processo de produção da linhagem IBU/ASE-16 e uso das mesmas como obtenção de extratos para a produção de vacinas e de proteínas recombinantes candidatas a biofármacos e acaricidas, produção de kits diagnósticos para a detecção de antígenos e/ou anticorpos para uso animal e humano, obtenção de clones para uso de genotipagem e utilização como substrato para isolamento e cultivo de patógenos.
Abstract:
La presente invención se refiere a una composición farmacéutica conformada por baba de caracol Helix aspersa müller (Cryptophalus aspersus ) (20% a 50%), extracto de manzanilla (1-4%), propóleo (1-4%) y aditivos y/o excipientes farmacéuticamente aceptables para formar una formulación de viscosidad baja, intermedia o alta (10 a 1000 Pa-s). Dicha composición en forma de loción, jabón, crema o gel, embebido en tela tipo gasa en forma de parche para ser aplicada sobre lesiones de los diversos tipos de rosácea. La composición puede contener además extractos naturales tales como extracto de caléndula, miel y aceites vegetales. Se reivindica además el procedimiento de obtención de la composición y su uso para preparar un medicamento o dispositivo para prevenir, tratar o curar lesiones derivadas de la rosácea, en la piel del rostro o del cuerpo.
Abstract:
The invention relates to an ointment for the treatment of internal haemorrhoids, able to avoid the advanced stages of the disease and the need for surgical intervention on long term. The ointment for the treatment of hemorrhoidal disease, according to the invention, especially for treating internal hemorrhoids grades I and II comprise axungia (animal fat), lanolin, white vaseline, camphor, calcium carbonate, eucalyptus oil, ethanol (ethyl alcohol) and preservatives. The ointment implementation and testing were structured in two phases, namely: a product design phase and a test phase (the testing was performed at the Faculty of Medicine and Pharmacy of the University "Dunarea de Jos"). In the first phase it was conducted the biochemical characterization of the microbiological and functional product and in the second phase it was conducted the selection of the group of patients, the clinical and para-clinical assessment of patients, in order to exclude possible pathologies caused or contributing to hemorrhoidal disease.
Abstract translation:本发明涉及用于治疗痔疮的软膏,其能够避免疾病的晚期阶段和长期需要手术干预。 根据本发明,用于治疗痔疮疾病的软膏,特别是用于治疗I型和II型痔疮的内痔,包括轴突(动物脂肪),羊毛脂,白凡士林,樟脑,碳酸钙,桉树油,乙醇(乙醇)和防腐剂 。 软膏实施和测试分两个阶段进行,分别是:产品设计阶段和测试阶段(测试在University of Medicine and Pharmacy of University“Dunarea de Jos”)进行。 在第一阶段进行微生物和功能性产品的生物化学表征,第二阶段进行了患者组的选择,患者的临床和临床评估,以排除引起的可能的病理或 有助于痔疮疾病。
Abstract:
This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.